By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Dako today said that it has signed an agreement with Bristol-Myers Squibb to develop pharmacogenomics tests to identify patients that are more likely to respond to drugs being developed by the drug firm.

The deal builds on a similar agreement between the firms reached in 2008. Terms of the newest agreement were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genomic study of group B Streptococcus evolution, selection on the X chromosome in great apes, and more.

Changing the fat and fiber content of people's diets affects their gut microbiome, metabolome, and colon cancer risk, researchers say.

Broken links are found throughout academic publications, and some services are trying to combat such link decay.

Nick Stockton at Wired says that a pause in studying genome-editing tools should be used to find a path forward.